Skip to main content

Report: New Cholesterol Drugs Too Costly

Newly approved drugs to lower cholesterol are priced much too high, according to the Institute for Clinical and Economic Review.

Republish
Lead image for this article

Newly approved drugs to lower cholesterol are priced much too high, according to the Institute for Clinical and Economic Review, an outside nonprofit which monitors cost and care issues. The companies that make the new drugs question the nonprofit’s methodology and some pharmacies have been pressing for significant discounts. (Wall Street Journal)

Texans need truth. Help us report it.

Independent Texas reporting needs your support. The Texas Tribune delivers fact-based journalism for Texans, by Texans — and our community of members, the readers who donate, make our work possible. Help us bring you and millions of others in-depth news and information. Will you support our nonprofit newsroom with a donation of any amount?

Yes, I'll donate today

Information about the authors

Madlin Mekelburg’s staff photo

Learn about The Texas Tribune’s policies, including our partnership with The Trust Project to increase transparency in news.

Explore related story topics